Search
for

    Did you mean Steroid 5 Alpha-Reductase 2?
    GlossarySteroid 5 Alpha-Reductase 2

    enzyme converting testosterone to potent androgen dihydrotestosterone (DHT)

    Steroid 5 Alpha-Reductase 2 (also known as 5α-Reductase Type 2 or SRD5A2) is an enzyme that converts testosterone into dihydrotestosterone (DHT), a more potent androgen. This enzyme plays a crucial role in the development of male characteristics and is also implicated in conditions like male pattern baldness and benign prostatic hyperplasia.

    Related Terms

    Learn

    3 / 3 results

      learn Clascoterone

      a novel topical treatment that inhibits DHT on androgen receptors

      learn Hydrocortisone

      a synthetic cortisol used for anti-inflammatory effects

    Research

    5 / 1000+ results

    Community Join

    5 / 484 results

      community Trying to understand finasteride side effects and post finasteride syndrome

      in Finasteride/Dutasteride  74 upvotes 4 years ago
      The conversation discusses the side effects of finasteride, including low libido and erectile dysfunction, and the possibility of these effects being permanent, known as post-finasteride syndrome (PFS). Some users report personal experiences with PFS and debate whether the condition is real, with varying opinions on the reversibility of side effects and the role of individual biology.

      community Dutasteride broked my liver (maybe)

      in Finasteride/Dutasteride  8 upvotes 1 year ago
      A user shared their experience with high cholesterol, glucose, and potential metabolic syndrome after using Finasteride and Dutasteride for hair loss. They plan to improve their health with diet and exercise before considering medication.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 2 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.